Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Lower-Toxicity Chemotherapy in Elderly Breast Cancer Patients
NCT03858322Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of Paclitaxel Micelles for Injection, carboplatin and cyclophosphamide in breast cancer (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Toxicity and receipt of planned therapy (feasibility) at 3 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03858322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858322.